Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study

Renáta Kószó, Dóra Sántha, László Büdi, József Erfán, Károly Győrfy, Zsolt Horváth, Judit Kocsis, László Landherr, Erika Hitre, Károly Máhr, Gábor Pajkos, Zsuzsanna Pápai, Zsuzsanna Kahán

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main objective of the study was to analyze the effectiveness and tolerability of XT therapy. A prospective, open-label, non-randomized, single-arm, multicenter, observational study was designed. All female patients were eligible whose metastatic breast cancer could be treated with the XT protocol according to the summary of product characteristics of the drugs. The median progression free survival was 9.9 ± 3.0 months. Time to treatment failure was 4.6 ± 5.1 months on average. The overall response rate was 28.9 %, the clinical benefit rate was 73.3 %. The treatment was discontinued in 35.6 % of patients due to disease progression and in 20.0 % due to adverse events (AE). 33 patients with a total of 73 AEs have been reported, and 13 of them had serious adverse events (SAE). The efficacy and the safety profile of XT chemotherapy proven in the study are consistent with the results demonstrated in randomized trials. First-line XT chemotherapy effectively improves the PFS in metastatic breast cancer.

Original languageEnglish
Pages (from-to)505-511
Number of pages7
JournalPathology and Oncology Research
Volume23
Issue number3
DOIs
Publication statusPublished - Jul 1 2017

    Fingerprint

Keywords

  • Capecitabine
  • Docetaxel
  • HER2-negative metastatic breast cancer
  • Toxicity

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Kószó, R., Sántha, D., Büdi, L., Erfán, J., Győrfy, K., Horváth, Z., Kocsis, J., Landherr, L., Hitre, E., Máhr, K., Pajkos, G., Pápai, Z., & Kahán, Z. (2017). Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study. Pathology and Oncology Research, 23(3), 505-511. https://doi.org/10.1007/s12253-016-0129-7